Instruction 1(b).

FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

	OMB APPROVAL									
	OMB Number: 3235-028 Estimated average burden									
	hours per response:	0.5								

Name and Address of Reporting Person*     Malik Shahzad				2. Issuer Name <b>and</b> Ticker or Trading Symbol Acutus Medical, Inc. [ AFIB ]									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)							
Widik SiidiiZdu														<b>&gt;</b>	Directo	or		10% O	wner	
(Last)	`	orst) (	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) 06/17/2021									Officer (give title below)  Other (specify below)					
2210 FA	RADAY AV	4.1	4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check App										- Ideala							
,					-   4. 11	Amer	nament,	Date	oi Origin	ai File	מ (ואוטוונוו/ט	ay/rear)		Line		Joini/Grou	ıb ⊢ııını	J (Check Ap	phicable	
(Street)														3	Form f	iled by Or	ne Repo	orting Perso	n	
CARLSI	BAD C.	A !	92008												Form 1 Persoi		ore thar	n One Repo	orting	
(City)	(S	tate) (	(Zip)																	
		Tab	le I - No	n-Deriv	ative	Sec	uritie	s Ac	quire	l, Di	sposed o	of, or B	enefic	ciall	y Owned	t				
D			2. Transa Date (Month/E		r) Ex	2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				5. Amour Securities Beneficia Owned For	s Illy ollowing	Form:	Direct III Indirect E str. 4)	. Nature of ndirect seneficial ownership		
									Code	v	Amount	(A) o (D)	r <sub>Pri</sub>	се	Transacti (Instr. 3 a	on(s)		,	nstr. 4)	
Common Stock 06/17				/2021	2021		A		1,8000	.,800 <sup>(1)</sup> A		\$ <mark>0</mark>	4,022			D				
Common Stock														65,	436			See ootnote <sup>(2)</sup>		
Common Stock												1,551,713				Gee ootnote <sup>(3)</sup>				
		Т	able II -						,		osed of converti	,		•	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	ned n Date,	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercis Expiration Date (Month/Day/Yea		sable and	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securitie Beneficia Owned Following Reported Transacti (Instr. 4)	e C s F ally D o g (I	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amo or Num of Shar	ber						
Stock Options (Right to Buy)	\$16.66	06/17/2021			A		7,022		(4)		06/17/2031	Common Stock	7,0	22	\$0	7,02	22	D		

## **Explanation of Responses:**

- 1. Each annual restricted stock unit ("Annual RSU") will be scheduled to vest as to all of the shares of Common Stock ("Shares") subject to such Annual RSU on the first anniversary of the date of grant of such Annual RSU, if on such date the Reporting person has remained in continuous service as a director
- 2. These shares are held by Advent Life Sciences LLP ("Advent"). The Reporting Person is a general partner of Advent, and disclaims beneficial ownership of the securities held by Advent except to the extent of his indirect pecuniary interest therein.
- 3. These shares are held by Advent Life Sciences Fund I LP. Advent is the general partner of Advent Life Sciences Fund II LP and the Reporting Person is a general partner of Advent. The Reporting Person disclaims beneficial ownership of the securities held by Advent Life Sciences Fund II LP except to the extent of his indirect pecuniary interest therein.
- 4. Each annual stock option (the "Annual Option") will be scheduled to vest and become exercisable as to all of the Shares subject to such Annual Option on the first anniversary of the date of grant of such Annual Option, if on such date the Reporting Person has remained in continuous service as a director.

/s/ Tom Sohn as attorney-in-

06/21/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.